Results 191 to 200 of about 39,565,656 (306)

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024). [PDF]

Biomolecules
Chatzipieris FP, Petsas E, Lambrinidis G, Matsoukas JM, Mavromoustakos T.   +4 more
europepmc   +1 more source

Sex-dependent effects of angiotensin II type 1 receptor blocker on molecular and behavioral changes induced by single prolonged stress. [PDF]

Behav Brain Res, 2023
Ortiz-Nazario E, Denton-Ortiz CM, Soto-Escobar LDM, Mateo-Mayol Z, Colon-Romero M, Hernandez-Lopez A, Porter JT.   +6 more
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Newly Developed Mimetic Peptides for Angiotensin II Type 1 Receptor Attenuate Doxorubicin-Induced c-Jun N-Terminal Kinase Activation, a Marker of Pro-Apoptotic Stress Signaling. [PDF]

Biomedicines
Matsuo Y, Suematsu Y, Miura SI.
europepmc   +1 more source

Inhibition of angiotensin II type 1 receptor reduces oxidative stress damage to the intestinal barrier in severe acute pancreatitis. [PDF]

Kaohsiung J Med Sci, 2023
Gao ZY, Jiang YJ, Wang J, Li C, Zhang DL.   +4 more
europepmc   +1 more source

Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. [PDF]

RMD Open
van der Wouden KE, Ahmed S, van Oostveen WM, Hoekstra EM, Liem SIE, Huizinga TWJ, Toes REM, Voskuyl AE, Riemekasten G, Fehres CM, Vonk M, de Vries-Bouwstra JK.   +11 more
europepmc   +1 more source

The Influence of Antibodies against Angiotensin II Type-1 Receptor on the Outcome of Kidney Transplantation: A Single-Center Retrospective Study. [PDF]

J Clin Med, 2023
Filiopoulos V, Vittoraki A, Vallianou K, Bellos I, Markaki P, Liapis G, Marinaki S, Iniotaki A, Boletis IN.   +8 more
europepmc   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

Epilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper, Zining Liu, Aristea S. Galanopoulou, Gernot Hlauschek, Benjamin Sinclair, Wai Lam Leung, Stefanie Dedeurwaerdere, Elisabeth Doran, Solomon L. Moshé, David C. Henshall, Ozlem Akman, Pablo M. Casillas‐Espinosa   +11 more
wiley   +1 more source

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. [PDF]

Fundam Clin Pharmacol
Deminice R, Cella PS, Borsari AL, Padilha CS, de Oliveira VHF.   +4 more
europepmc   +1 more source

Atrial Electrical Remodeling in Mice With Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor. [PDF]

J Am Heart Assoc, 2022
Demers J, Ton AT, Huynh F, Thibault S, Ducharme A, Paradis P, Nemer M, Fiset C.   +7 more
europepmc   +1 more source